Antibodies to canine and feline oncostatin m receptor beta and uses thereof
AssigneeZoetis Services LLC
InventorsGary Francis Bammert, Andrea Joy Gonzales
Life of this patent
Estimating the term…
Abstract
The invention provides an isolated antibody, or antigen-binding portion thereof that specifically binds to canine or feline Oncostatin M receptor Beta (OSMR-β) or both, wherein the antibody antagonizes IL-31-mediated signaling or OSM-mediated signaling or both in a canine and/or feline cell.
Claims35
An isolated antibody, or antigen-binding portion thereof that specifically binds to canine or feline Oncostatin M receptor Beta (OSMR-β) or both, wherein the antibody antagonizes IL-31-mediated signaling or OSM-mediated signaling or both in a canine and/or feline cell.
A host cell that produces an isolated antibody or antigen-binding portion thereof comprising at least one of the following combinations of complementary determining region (CDR) sequences:
- 1) 02D09:
- variable heavy (VH)-CDR1 of SEQ ID NO:
- 1
- (DYGMH),
- VH-CDR2 of SEQ ID NO:
- 2 (YISSGSRAVFFADTVKG),
- VH-CDR3 of SEQ ID NO:
- 3 (DRYDGRGFAY),
- variable light (VL)-CDR1 of SEQ ID NO:
- 4
- (RASQSISNNLH),
- VL-CDR2 of SEQ NO:
- 5 (YASQSIS), and
- VL-CDR3 of SEQ ID NO:
- 6 (QQSNSWPLT);
- 2) 09E09:
- VH-CDR1 of SEQ ID NO:
- 7 (SYAMS),
- VH-CDR2 of SEQ ID NO:
- 8 (YISSGGDYIYYADTVKG),
- VH-CDR3 of SEQ ID NO:
- 9 (DPITGTFAY),
- VL-CDR1 of SEQ ID NO:
- 10 (RASQDINNYLN),
- VL-CDR2 of SEQ ID NO:
- 11 (YTSTLHS), and
- VL-CDR3 of SEQ ID NO:
- 12 (QQGNTLPWT);
- 3) 10F07:
- VH-CDR1 of SEQ ID NO:
- 13 (SYAMS),
- VH-CDR2 of SEQ ID NO:
- 14 (YISSGGDYFYYADTVKG),
- VH-CDR3 of SEQ ID NO:
- 15 (DPITGTFAY),
- VL-CDR1 of SEQ ID NO:
- 16 (RASQDITNYLN),
- VL-CDR2 of SEQ ID NO:
- 17 (YTSTLHS), and
- VL-CDR3 of SEQ ID NO:
- 18 (QQGHMLPWT);
- 4) 14C04:
- VH-CDR1 of SEQ ID NO:
- 19 (NYWMN),
- VH-CDR2 of SEQ ID NO:
- 20 (QIYPGHVNTNYNGNFKD),
- VH-CDR3 of SEQ ID NO:
- 21 (SADNSGFVLFAY),
- VL-CDR1 of SEQ ID NO:
- 22 (RASKSVSTSGYSYLH),
- VL-CDR2 of SEQ ID NO:
- 23 (LASNLES), and
- VL-CDR3 of SEQ ID NO:
- 24 (QHSRELPLT);
- 5) 19F07:
- VH-CDR1 of SEQ ID NO:
- 25 (DYYMA),
- VH-CDR2 of SEQ ID NO:
- 26 (NINYDGSSTYYLDSLKS),
- VH-CDR3 of SEQ ID NO:
- 27 (GLTWDFDV),
- VL-CDR1 of SEQ ID NO:
- 28 (KASQDVDTAVA),
- VL-CDR2 of SEQ ID NO:
- 29 (LASTRHT), and
- VL-CDR3 of SEQ ID NO:
- 30 (QQYSRFPLT);
- or
- 6) CDR variants of 1, 2, 3, 4, or 5.
An isolated nucleic acid comprising a nucleic acid sequence encoding at least one of the following combinations of complementary determining region (CDR) sequences:
- 1) 02D09:
- variable heavy (VH)-CDR1 of SEQ ID NO:
- 1
- (DYGMH),
- VH-CDR2 of SEQ ID NO:
- 2 (YISSGSRAVFFADTVKG), and
- VH-CDR3 of SEQ ID NO:
- 3 (DRYDGRGFAY);
- 2) 09E09:
- VH-CDR1 of SEQ ID NO:
- 7 (SYAMS),
- VH-CDR2 of SEQ ID NO:
- 8 (YISSGGDYIYYADTVKG), and
- VH-CDR3 of SEQ ID NO:
- 9 (DPITGTFAY);
- 3) 10F07:
- VH-CDR1 of SEQ ID NO:
- 13 (SYAMS),
- VH-CDR2 of SEQ ID NO:
- 14 (YISSGGDYFYYADTVKG), and
- VH-CDR3 of SEQ ID NO:
- 15 (DPITGTFAY);
- 4) 14C04:
- VH-CDR1 of SEQ ID NO:
- 19 (NYWMN),
- VH-CDR2 of SEQ ID NO:
- 20 (QIYPGHVNTNYNGNFKD), and
- VH-CDR3 of SEQ ID NO:
- 21 (SADNSGFVLFAY);
- 5) 19F07:
- VH-CDR1 of SEQ ID NO:
- 25 (DYYMA),
- VH-CDR2 of SEQ ID NO:
- 26 (NINYDGSSTYYLDSLKS), and
- VH-CDR3 of SEQ ID NO:
- 27 (GLTWDFDV);
- or
- 6) CDR variants of 1, 2, 3, 4, or 5.
A nucleic acid sequence encoding at least one of the following combinations of CDR sequences:
- 1) 02D09:
- variable light (VL)-CDR1 of SEQ ID NO:
- 4
- (RASQSISNNLH),
- VL-CDR2 of SEQ NO:
- 5 (YASQSIS), and
- VL-CDR3 of SEQ ID NO:
- 6 (QQSNSWPLT);
- 2) 09E09:
- VL-CDR1 of VL-CDR1 of SEQ ID NO:
- 10
- (RASQDINNYLN),
- VL-CDR2 of SEQ ID NO:
- 11 (YTSTLHS), and
- VL-CDR3 of SEQ ID NO:
- 12 (QQGNTLPWT);
- 3) 10F07:
- VL-CDR1 of SEQ ID NO:
- 16 (RASQDITNYLN),
- VL-CDR2 of SEQ ID NO:
- 17 (YTSTLHS), and
- VL-CDR3 of SEQ ID NO:
- 18 (QQGHMLPWT);
- 4)14C04:
- VL-CDR1 of SEQ ID NO:
- 22
- (RASKSVSTSGYSYLH),
- VL-CDR2 of SEQ ID NO:
- 23 (LASNLES), and
- VL-CDR3 of SEQ ID NO:
- 24 (QHSRELPLT);
- 5) 19F07:
- VL-CDR1 of SEQ ID NO:
- 28 (KASQDVDTAVA),
- VL-CDR2 of SEQ ID NO:
- 29 (LASTRHT), and
- VL-CDR3 of SEQ ID NO:
- 30 (QQYSRFPLT);
- or
- 6) CDR variants of 1, 2, 3, 4, or 5.
Dependencies are inferred from the claim text.